medigraphic.com
ISSN 0188-9796 (Impreso)

2006, Número 3

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2006; 14 (3)


Indicaciones de la terapia de reemplazo

Cabeza GÁ

Idioma: Español
Referencias bibliográficas: 39
Paginas: 199-204
Archivo PDF: 81.82 Kb.


FRAGMENTO

Hace 10 años la terapia hormonal de reemplazo, fundamentalmente los estrógenos, parecían algo menos que la “fuente de la juventud” para las mujeres en la postmenopausia. Hablábamos de protección cardiovascular, de la osteoporosis y del deterioro mental. En este lapso algunos reportes han modificado los criterios en relación con estas sustancias y lo que se espera de ellas. En todos los análisis recientes sobre el tema hay un “antes” y un “después” del estudio WHI, que se repite en forma obligada en cada revisión del tema.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Anderson GL, Judd HL et al. Women’s Health Initiative. Effects of estrogen plus progestin on gynecologic cancer and associated diagnostic procedures; the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1739-1748.

  2. Gracia CR, Sammel MD, Freeman EW et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005; 12: 128-135.

  3. Bringham and Women’s Hospital. Menopause: A guide to management. Boston Ma. Brigham and Women’s Hospital, 2005: 15.

  4. NIH State-of-the-Science Panel. National Institutes of Health State-of-the Science. Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142: 1003-1013.

  5. Cochrane review. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. The Cochrane library, Issue 2, 2006.

  6. Carr MC. The emerge of the metabolic syndrome with menopause. J Clin Endocr Metab 2003; 88: 2404-2411.

  7. Norman RJ, Flight JHK, Rees MCP. Oestrogen and progesteron hormon replacement therapy for peri menopausal and post-menopausal women: weight and body fat distribution. The Cochrane Database of Systematic Reviews 2006, Issue 2.

  8. Birkhauser M. Depression, menopause and estrogens: is there a correlation? Maturitas 2002; 15: 41 Suppl.

  9. Medscape Diabetes & Endocrinology. Coverage of the 2nd World Congress of Women’s Menthal Health, 2004.

  10. Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil and Steril 2004; 82: 273-289.

  11. Simon JA. Safety of estrogen/androgen regimens. J Reprod Med 2001; 46 (3 Suppl.): 281-290.

  12. American Society for Reproductive Medicine. Estrogens: Using lower doses and alternative delivery systems. Fertil and Steril 2001: 1065-1079.

  13. Hickey M, Saunders CM, Stuckey BGA. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet 2005; 6: 687-695.

  14. Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes. Systematic review and meta-analysis. JAMA 2006; 295: 2057-2070.

  15. The Journal of the American Menopause Society. Treatment of menopause associated vasomotor symptoms: position statement of the American Menopause Society. 2004; 11: 11-33.

  16. Viltinghoff E, Shlipak MG, Varosy PD et al. For the Heart and Estrogen Replacement Study. Ann Inter Med 2003; 138: 81-89.

  17. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684.

  18. Paganini-Hill A, Corrada M, Kawas C. Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause 2006; 13: 12-18.

  19. Colditz GA, Hankinson SE et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.

  20. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovascular Research 2005; 66: 295-306.

  21. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712.

  22. Recommendations for Hormone Therapy by National Organizations and their Implications for the Practitioner. Annual Meeting of the ASRM, panel of experts. Estrogens: using lower doses and alternative delivery systems. Amer Soc Reprod Med 2003.

  23. Estrogen and progesterone use in peri and postmenopausal women. Sept. 2003 position Statement of the North American Menopause Society.

  24. Chen WY, Manson JE, Hankinson SE et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Inter Med 2006; 166: 166.

  25. Lindsay R, Gallagher JCH, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-2676.

  26. Prestwood KM, Kenny AM, Klepplinger A, Kullforff M. Ultralow-dose micronized 17 b-estradiol and bone density and bone metabolism in older women. A randomized controlled trial. JAMA 2003; 290: 1042-1048.

  27. Barrett-Connor E, Wehren LE, Siris ES et al. Regency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause 2003; 10: 412-419.

  28. Yates J, Barrett-Connor E, Barlas S et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from of National Osteoporosis Risk Assessment. Obstet & Gynecol 2004; 103: 440-446.

  29. The Cochrane Library. Tamoxifen for early breast cancer. Early breast cancer trialists’ collaborative group. Issue 2, 2006.

  30. Ettinger B, Black B, Mitiak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637-645.

  31. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocr Metab 2002; 87: 16-23.

  32. Medical News Today, 20 Feb 2006. Organon to close the LIFT study.

  33. Mayo Clinic News en Español. 12 de mayo de 2005. Los investigadores de la Mayo Clinic informan sobre la efectividad de los tratamientos para los bochornos.

  34. Vanderschueren D, Vandenput L, Boonen S et al. Androgens and bone. Edocr Rev 2004; 25: 389-425.

  35. Davis SR, Davison SL, Donath M, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005; 294: 294-291.

  36. Testosterone therapy. Produced by the Women’s Health Program, Monash University.

  37. Kalantaridou SN, Naka KK, Papanicolaou E et al. Impaired Endothelial Function in Young Women with Premature Ovarian Failure: Normalization with Hormone Therapy. The Journal of Clinical Endocrinology & Metabolism 2004; 89:

  38. Gelfand MM. Role of androgens in surgical menopause. J Obstet Gynecol 1999; 180: S325-S327.

  39. Baron JA, Farahmand BY, Weiderpass E et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med 2001; 161: 983-988.




2020     |     www.medigraphic.com